News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s Avastin Strikes Out Again With National Institute for Clinical Excellence (NICE)



8/22/2012 6:45:35 AM

NICE has now issued final guidance saying it does not recommend Avastin (bevacizumab), in combination with Roche’s Xeloda, for the firstline treatment of metastatic breast cancer in people for whom treatment with other chemotherapy options including taxanes or anthracyclines, is not considered appropriate. The watchdog says its recommendation has remained constant throughout the process of guidance development - i.e., not recommending the treatment - adding that neither Roche nor other consultees had raised objections to NICE at any stage. Sir Andrew Dillon, NICE’s chief executive, said: “We can’t recommend a drug that has not been shown to work as well as, or better than, current treatments and costs much more.

Read at InPharm.com
Read at News Release
Read at The Independent


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES